SPRO vs. MGNX, OGI, INBX, MDWD, ARTV, PRQR, NLTX, PROC, ZNTL, and HURA
Should you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include MacroGenics (MGNX), Organigram (OGI), Inhibrx (INBX), MediWound (MDWD), Artiva Biotherapeutics (ARTV), ProQR Therapeutics (PRQR), Neoleukin Therapeutics (NLTX), Procaps Group (PROC), Zentalis Pharmaceuticals (ZNTL), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry.
Spero Therapeutics vs.
Spero Therapeutics (NASDAQ:SPRO) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.
Spero Therapeutics has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500.
In the previous week, Spero Therapeutics and Spero Therapeutics both had 1 articles in the media. Spero Therapeutics' average media sentiment score of 0.50 beat MacroGenics' score of -0.55 indicating that Spero Therapeutics is being referred to more favorably in the media.
Spero Therapeutics has a net margin of 3.30% compared to MacroGenics' net margin of -69.07%. Spero Therapeutics' return on equity of 4.03% beat MacroGenics' return on equity.
Spero Therapeutics has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Spero Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 465.61%. MacroGenics has a consensus price target of $7.63, suggesting a potential upside of 155.44%. Given Spero Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Spero Therapeutics is more favorable than MacroGenics.
MacroGenics received 218 more outperform votes than Spero Therapeutics when rated by MarketBeat users. However, 69.57% of users gave Spero Therapeutics an outperform vote while only 62.28% of users gave MacroGenics an outperform vote.
25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 4.5% of Spero Therapeutics shares are held by insiders. Comparatively, 11.3% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Spero Therapeutics beats MacroGenics on 11 of the 17 factors compared between the two stocks.
Get Spero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spero Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SPRO) was last updated on 1/21/2025 by MarketBeat.com Staff
Free SPRO Stock Alerts